A mutation of EPT1 (SELENOI) underlies a new disorder of Kennedy pathway phospholipid biosynthesis. by Ahmed, MY et al.
REPORT
A mutation of EPT1 (SELENOI) underlies a new
disorder of Kennedy pathway phospholipid
biosynthesis
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Mutations in genes involved in lipid metabolism have increasingly been associated with various subtypes of hereditary spastic para-
plegia, a highly heterogeneous group of neurodegenerative motor neuron disorders characterized by spastic paraparesis. Here, we report
an unusual autosomal recessive neurodegenerative condition, best classiﬁed as a complicated form of hereditary spastic paraplegia,
associated with mutation in the ethanolaminephosphotransferase 1 (EPT1) gene (now known as SELENOI), responsible for the ﬁnal
step in Kennedy pathway forming phosphatidylethanolamine from CDP-ethanolamine. Phosphatidylethanolamine is a glyceropho-
spholipid that, together with phosphatidylcholine, constitutes more than half of the total phospholipids in eukaryotic cell membranes.
We determined that the mutation deﬁned dramatically reduces the enzymatic activity of EPT1, thereby hindering the ﬁnal step in
phosphatidylethanolamine synthesis. Additionally, due to central nervous system inaccessibility we undertook quantiﬁcation of phos-
phatidylethanolamine levels and species in patient and control blood samples as an indication of liver phosphatidylethanolamine
biosynthesis. Although this revealed alteration to levels of speciﬁc phosphatidylethanolamine fatty acyl species in patients, overall
phosphatidylethanolamine levels were broadly unaffected indicating that in blood EPT1 inactivity may be compensated for, in part,
via alternate biochemical pathways. These studies deﬁne the ﬁrst human disorder arising due to defective CDP-ethanolamine biosyn-
thesis and provide new insight into the role of Kennedy pathway components in human neurological function.
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Introduction
Hereditary spastic paraplegia (HSP) encompasses a highly het-
erogeneous group of disorders characterized clinically by fea-
tures of upper motor neuron lesion including spasticity,
weakness, increased tendon reﬂexes and upward going plan-
tar reﬂexes; the term complex HSP is used when these features
are associated with other neurological or non-neurological
features (Finsterer et al., 2012; Fink, 2013; Lo Giudice
et al., 2014; Noreau et al., 2014). Many genes have been
implicated in the pathology of HSP, encoding molecules
with diverse functional roles (Lo Giudice et al., 2014;
Noreau et al., 2014), including a number of genes involved
in lipid metabolism (CYP7B1, CYP2U1, DDHD1, DDHD2,
BSCL2, ERLIN2, FA2H and PNPLA6/NTE) (Windpassinger
et al., 2004; Rainier et al., 2008; Goizet et al., 2009; Alazami
et al., 2011; Schuurs-Hoeijmakers et al., 2012; Tesson et al.,
2012; Cao et al., 2013; Gonzalez et al., 2013). Here, we
investigated four individuals from a single consanguineous
Omani family aged between 19 months and 15 years (Fig.
1A) that presented with an unusual neurodegenerative condi-
tion best categorized clinically as a complex form of HSP with
brain white matter involvement.
Materials and methods
Standard protocol approvals, regis-
trations, and patient consents
Informed consent was obtained from participating individuals
or their legal guardians and research was performed according
to institutional, national and international human subject re-
search guidelines.
Genetic studies
Genomic DNA samples were extracted from peripheral blood fol-
lowing standard protocols. Genome-wide genotyping was carried
out using Illumina HumanCytoSNP-12 v2.1SNP arrays. Data
output was visualized in Illumina’s GenomeStudio software.
Multipoint linkage analysis was performed assuming a recessive
mode of inheritance, full penetrance, and a disease allele fre-
quency of 0.0001 using SimWalk2 (Sobel and Lange, 1996).
Whole exome sequencing was performed by Otogenetics Corp.
using the SureSelect Human All Exon V4 (Agilent Technologies)
exome enrichment kit on an Illumina HiSeq2000. Reads were
analysed on the DNAnexus platform for exome coverage, SNP/
InDel variant calling and quality ﬁltering. The exome sequencing
produced 21907356 mapped 100bp paired-end reads, matching
95.92% of targeted sequences adequately covered for variant
calling (410 coverage; mean depth, 38.4 ).
The identiﬁed putative mutations were validated by PCR
ampliﬁcation followed by di-deoxy sequence analysis (Applied
Biosystems 3130 DNA Sequencer, Life Technologies). Primer
design to amplify the coding exon 5 of the SELENOI/EPT1
gene was done using Primer3 online tool (Rozen and Skaletsky,
2000). Primer sequence speciﬁcity was veriﬁed by using the
UCSC In-Silico PCR tool and their sequences were screened
to exclude common single nucleotide polymorphisms.
Expression of human EPT1 in yeast
Open reading frames encoding full-length wild-type human
SELENOI/EPT1, and the c.335G4C (p.Arg112Pro) mutated
allele identiﬁed in patients, were subcloned into the
Saccharomyces cerevisiae expression vector p416-GPD with a 3’
extension encoding Myc and DDK tags allowing for constitutive
expression from the GPD1 promoter. The TGA codon encoding
selenocysteine at amino acid 387 of EPT1 was changed to a
cysteine encoding TGT codon by site-directed mutagenesis.
Plasmids bearing the wild-type and the mutant allele of human
SELENOI/EPT1 were transformed into the yeast strain HJ091
(ept1-1 cpt1::LEU2), which is devoid of endogenous ethanolami-
nephosphotransferase activity (Henneberry and McMaster, 1999;
Henneberry et al., 2000). Yeast cells containing the SELENOI/
EPT1 expression plasmids were grown to mid-log phase and
whole cell extracts were prepared and fractionated into soluble
and membranous fractions by centrifugation at 100000g for 1h.
Western blots using anti-DDK antibodies were performed to
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determine EPT1 protein expression, with Pgk1 (cytosolic fraction)
and Dpm1 (membrane fraction) used as loading controls.
In vivo phospholipid radiolabelling
Yeast cells were grown to mid-log phase in 10ml of synthetic
deﬁned medium. Cells were pelleted, washed with synthetic
deﬁne medium without ammonium sulphate and resuspended
in 4ml of the same medium containing 14C-ethanolamine
(3mM, 244000 dpm/nmol). Cells were cultivated for 1h at
30C. At the end of the radiolabelling period cells were har-
vested, washed with ice-cold water and processed for lipid ex-
traction. Brieﬂy, cells were resuspended in 1ml of CHCl3/
CH3OH (1:1) and disrupted by bead beating for 1min at
4C. The beads were washed with 1ml of CHCl3/CH3OH
(2:1), and 1.5ml of H2O and 1ml of CHCl3/CH3OH (5:1)
were added to the combined supernatant to facilitate phase sep-
aration. Phospholipids in the organic phase were analysed by
thin layer chromatography on Whatman Silica Gel 60A plates
using the solvent system CHCl3/CH3OH/H2O/CH3COOH (70/
30/2/2). Plates were scanned with a BioScan radiolabel imaging
scanner, and the bands corresponding to phosphatidylethanola-
mine (PE) and phosphatidylcholine (PC) were scraped into vials
for liquid scintillation counting (Henneberry and McMaster,
1999). Lipid phosphorous was determined as described by
Ames and Dubin (1960). Data represent the mean  standard
error of three independent determinations.
Lipidomic analysis of blood samples
Whole blood from the four affected individuals and their par-
ents (carriers) as well as from ﬁve controls was taken for blood
phospholipid measurements. Lipid extraction was performed
using a modiﬁed Bligh and Dyer extraction (Bligh and Dyer,
1959). Brieﬂy, 10 ml of blood was transferred into weighed
2.0ml Eppendorf tubes. One hundred and eighty microlitres
of chilled chloroform/methanol (1:2; v/v) containing internal
standards was added. The incubate was vortexed to mix
(15 s) with agitation on a thermo mixer (400 rpm) at 4C in
the dark for 1 h (single phase). Sixty microliters of chilled
Figure 1 Genetic and clinical summary of the pedigree investigated. (A) The Omani pedigree with a pictorial representation of the
homozygous SNP genotypes across the critical interval (red hashed box) with ‘A’ and ‘B’ genotypes indicated by blue and yellow bars. SELENOI/
EPT1 genotypes shown in red (plus sign indicates presence of c.335 G4C alteration, negative sign indicates wild-type). (B) Sequence
electropherograms showing the DNA encompassing the SELENOI/EPT1 c.335 G4C alteration. (C) Species alignment of EPT1 amino acids
encompassing the altered p.Arg112 residue showing stringent conservation within the CDP catalytic motif. (D–G) Clinical features of affected
individuals. (D) Photograph of Patient V:1 showing bifid uvula. (E) Retinal photograph from the right eye of Patient V:5 showing: mild retinal vessel
tortuosity, a dull macular reflex and a mild retinal pigment epithelium level pigmentary disturbance most noticeable inferiorly. (F and G) Brain MRI
scan of Patient V:6 reveals bilateral symmetrical periventricular hyperintensity in the trigon, frontal subcortical white matter and U fibre. All four
children displayed similar MRI findings.
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chloroform and 50 ml chilled Milli-Q water was added and
the sample was then vortexed to mix (15 s) and centrifuged at
10 000 rpm for 7min to separate the phases. The lower or-
ganic phase was transferred into clean 2.0ml microfuge tube
(ﬁrst organic extract). The ﬁrst organic extract was centrifuged
in a vacuum concentrator (SpeedVac) for 10min. The remain-
ing aqueous phase was re-extracted using 100 ml of chilled
chloroform. It was then vortexed to mix (15 s), and centrifuged
at 10 000 rpm for 7min to separate the phases. Lower organic
phase was transferred into the ﬁrst organic extract. The pooled
organic extract was dried in a vacuum concentrator
(SpeedVac). The lipid extract was resuspended with 200 ml of
chilled chloroform/methanol (1:2; v/v). It was then stored at
80C until mass spectrometry analysis.
For LC/MS analysis, 20ml aliquots of samples were added
into glass vials with glass inserts. A QC sample was generated
by pooling 10ml of each sample together. The sample injection
volume was 2ml. Lipids were separated using gradient elution.
Mobile phase A: 40% acetonitrile / 60% 10mM ammonium
formate in H2O; mobile phase B: 90% isopropanol / 10%
10mM ammonium formate in H2O. Column: Agilent Zorbax
Eclipse plus C18, length: 50mm, internal diameter: 4.6mm,
particle size: 1.8mm. Column temperature: 40C. The ﬂow
rate was 0.4ml/min and the gradient as follows: initial: 20%
B, increase to 60% B in 2min, increase to 100% B in 5min,
stay at 100% B for 2min, decrease to 20% B in 0.01 mins,
keep at 20% B until end of run (10.8min).
Samples were randomized using Excel for injection into LC/
MS instrument and the QC sample was injected after every six
samples. To avoid carry over, every QC injection was followed
by a blank injection. This injection sequence was repeated three
times (technical triplicates). Quantiﬁcation data were extracted
using Agilent MassHunter Quantitative Analysis (QQQ) soft-
ware. The data were manually curated to ensure that the soft-
ware integrated the correct peaks. Area under the curve (AUC)
of lipids were normalized to AUC of internal standards.
Results
Clinical studies
Four children from an extended Omani pedigree aged be-
tween 19 months and 15 years and affected by a complex
neurodegenerative phenotype. The affected individuals pre-
sented in infancy/early childhood with delayed gross motor
development, progressive spastic paraperesis and gradual de-
cline in motor function. The oldest affected individual has
evidence of upper limb involvement. All affected individuals
also manifest an apparently non-progressive mild intellectual
impairment. A delay in language acquisition was universal,
with dysarthria becoming more noticeable with advancing
age. Neuroimaging in all four individuals revealed increased
T2 intensity signal in the periventricular white matter. The
oldest affected child had neurophysiological evidence of a
demyelinating peripheral neuropathy; however, upper
motor neuron signs predominate over any clinical manifest-
ations of this. Associated variable features included micro-
cephaly, seizure activity and biﬁd uvula with or without cleft
palate. Generalized retinal pigment epithelium level
pigmentary disturbance was seen in two of the children,
full-ﬁeld electroretinography, performed in one of these chil-
dren was consistent with cone-rod dysfunction. Therefore, a
clinical diagnosis of complicated hereditary spastic paraple-
gia had been assigned to these families, although there are
additional features present in some individuals that provide
evidence of a broader phenotype associated with disturbance
of the Kennedy pathway phospholipid cascade (Table 1).
Genetic studies
To determine the genomic location of the gene responsible, we
undertook genome-wide single nucleotide polymorphism (SNP)
genotyping of DNA extracted from blood from family mem-
bers assuming, autosomal recessive inheritance and that a foun-
der mutation was responsible. This identiﬁed a single notable
autozygous region of 21.75Mb on chromosome 2p, delimited
by markers rs4669407 and rs207423 (Fig. 1A and
Supplementary Fig. 1), likely to correspond to the disease
locus. To identify the causative mutation, we performed
whole exome sequencing on an affected family member
(Patient V:1). After ﬁltering the identiﬁed variants for call qual-
ity, potential pathogenicity, population frequency (0.01%) and
localization within the candidate interval a single sequence vari-
ant located within the disease locus was identiﬁed, in ethano-
laminephosphotransferase 1 (SELENOI/EPT1; NM_033505.2;
chr2:26,373,391G4C; c.335G4C; p.Arg112Pro; Fig. 1B).
The variant affects a stringently conserved arginine residue
(p.Arg112Pro; Fig. 1C), which is predicted to be damaging
by in silico analysis (PolyPhen-2 (Majava et al., 2007) and
PROVEAN (Choi et al., 2012), and was found to co-segregate
in the family as appropriate for an autosomal recessive condi-
tion (Fig. 1A), is not present in online genomic variant data-
bases (1000 Genomes, Exome Variant Server, and Exome
Aggregation Consortium (ExAC) and was also absent in 100
regional Omani control subjects.
Expression of human EPT1 in yeast
To determine the likely pathogenicity of the variant, we next
investigated the effect of the p.Arg112Pro mutation on EPT1
activity. SELENOI/EPT1 encodes a CDP-ethanolamine spe-
ciﬁc enzyme that catalyses the ﬁnal step in the synthesis of PE
via the Kennedy pathway (Fig. 2A) (Horibata and
Hirabayashi, 2007). EPT1 belongs to a superfamily of inte-
gral membrane phospholipid synthesising enzymes that cata-
lyse displacement of CMP from a CDP-alcohol by a second
alcohol with formation of a phosphodiester bond to synthe-
size a phospholipid. This family of enzymes contains a highly
conserved catalytic motif, the CDP-alcohol phosphotransfer-
ase motif DG(X2)AR(X8)G(X3)D(X3)D (Williams and
McMaster, 1998), which for EPT1 is found between amino
acid residues 107–129 (107DGKQAR112RTNSSTPLGELFD
HGLD129). As the sequence alteration described here affects
the highly conserved arginine residue (p.Arg112Pro) within
this CDP-alcohol phosphotransferase motif, we examined
whether the alteration affects EPT1 catalytic activity.
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In order to determine this, human EPT1 and mutant
EPT1Arg112Pro were expressed from a constitutive promoter
in a S. cerevisiae strain devoid of endogenous ethanolamine-
phosphotransferase activity, and their capacity to synthesize
PE was determined by metabolic labelling studies. Western
blots demonstrated that both human SELENOI/EPT1 alleles
were expressed in yeast at comparable levels indicating that
protein stability was not affected, were associated with the
Table 1 Clinical features of patients
Patient V:1 V:5 V:6 V:7
Age at time of
assessment (years)
15.06 7.28 3.12 1.60
Sex Male Male Male Female
Head circumference
(SDS/cm)
3.23 (51.0) 1.69 (51.0) 2.03 (48.7) 3.55 (44.0)
Height (SDS/cm) 2.24 (149.5) 2.97 (108) 2.17 (88.3) 1.93 (76.2)
Development:
Gross motor A few independent steps, grad-
ual decline in motor function
Cruises furniture, gradual de-
cline in motor function
Cruises furniture Crawling
Speech Dysarthric, nasal speech, short
sentences
Dysarthric, nasal speech, 2–
3-word sentences
A few single words Babbling
Intellectual disability Mild Mild Mild
Neurology:
Upper limb
Spasticity  x x x
Lower limb
Spasticity    
Hyperreflexia    
Ankle clonus   x 
Extensor plantar
responses
   
Brain MRI High intensity signal in the
periventricular trigonal area
with atrophy in surrounding
white matter
Increased T2 intensity signal in
periventricular and subcor-
tical white matter and along
optic radiation
Increased T2 signal intensity
in the periventricular white
matter
Increased T2 signal inten-
sity in the periventricular
region more pronounced
around the atria of the
lateral ventricles
Nerve Conduction
Studies
Motor conduction study of
median/ulnar and common
peroneal nerves – normal
CMAP parameters (ampli-
tude, latency, F-responses
and conduction velocity).
Normal (age 5 years) Borderline prolongation of
the median nerve motor
latencies, otherwise
normal (age 3 years)
Normal
Median/ulnar and sural nerve
sensory study – normal
Posterior tibial CMAP ampli-
tude – severely reduced
and dispersed, borderline
decline in conduction vel-
ocity. (age 11 years)
Ophthalmic
phenotype
Reduced visual acuity Photophobic Age appropriate visual
behaviour
Age appropriate visual
behaviour
No refractive error Reduced visual acuity Normal refraction Mild hyperopic astigmatism
No further phenotyping Mild hyperopic astigmatism Normal anterior segment Mild retinal vessel
tortuosity
Mild retinal vessel tortuosity RPE pigmentary disturbance Dull macular reflex
Generalized RPE level pigmen-
tary disturbance
No further phenotyping No further phenotyping
Dull macular reflex
Normal anterior segment
ffERG findings of cone-rod
dysfunction.
No further phenotyping
Cleft palate/bifid uvula Bifid uvula, cleft palate x High arched palate Bifid uvula
Height, weight and OFC Z-scores were calculated using a Microsoft Excel add-in to access growth references based on the LMS method (Pan and Cole, 2012) using a reference
European population (Cole et al., 1998).
SDS = standard deviation scores; = presence of a feature in an affected subject;  indicates absence of a feature in an affected subject; CMAP = compound muscle action potential;
RPE = retinal pigment epithelium; ffERG = full-field electroretinography.
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membrane fraction as would be expected for an integral
membrane protein, and exhibited their projected molecular
weight of 46kDa (Fig. 2B).
In vivo phospholipid radiolabelling
We next determined the capacity of human EPT1 and
mutant EPT1Arg112Pro to synthesize PE in vivo. To do so,
the level of radiolabelled ethanolamine incorporated into
phospholipid was determined as described previously
(Henneberry and McMaster, 1999). Radiolabelled ethanola-
mine is incorporated into PE by the CDP-ethanolamine path-
way, in yeast the PE synthesized by this pathway can be
converted to phosphatidylcholine (PC) by PE methyltrans-
ferases (Kodaki and Yamashita, 1987; Henry et al., 2012).
Thus, the total radiolabel present in the PE plus PC fraction
is indicative of the total activity of the ethanolaminepho-
sphotransferase enzyme present. The amount of radiola-
belled ethanolamine incorporated into phospholipid for
mutant EPT1Arg112Pro was dramatically diminished, being
only 3% that of wild-type EPT1 (Fig. 2C). Consistent with
this, previous enzyme activity studies of yeast Cpt1 deter-
mined that amino acid substitutions at this residue also
result in signiﬁcant decrease in enzyme activity (Williams
and McMaster, 1998). Thus, there is a substantive reduction
in EPT1 activity due to mutation of p.Arg112 to Pro, con-
sistent with a loss-of-function mutation.
Lipidomic analysis of blood samples
As we were unable to directly quantify PE levels in brain of
affected individuals, and as brain does not efﬂux PE into the
blood, we investigated the amount of PE in blood using
mass spectrometry as an indicator for liver EPT1 activity.
While there were notable increases in certain individual PE
species in patients (e.g. PE36:2, PE36:4 and PE38:5;
Supplementary Fig. 2A), there was no signiﬁcant difference
in levels of total PE (Supplementary Fig. 2B), PC, lysopho-
sphatidylcholine (LPC) or phophatidyl serine (PS) (not
shown) compared with controls. Given the variation in
other individual species between patients, controls and par-
ental carriers, we are not able to determine deﬁnitively
whether changes to individual biochemical species reﬂect ab-
normal biosynthesis as a result of the EPT1 mutation, or
coincidental natural variation. Thus while we are unable to
assess the outcome of the EPT1 mutation in brain, these
ﬁndings indicate that in blood a substantive decrease in
EPT1 activity does not affect overall PE levels in blood.
Discussion
Glycerophospholipids are the primary lipid species of eu-
karyotic cell membranes, of which the major classes include
PC and PE (Gibellini and Smith, 2010). PE is normally the
second most abundant phospholipid in eukaryotic mem-
branes after PC, constituting 25–45% of phospholipid con-
tent (Vance and Tasseva, 2013). PE provides vital structural
support to cellular membranes, sustains the function of in-
trinsic membrane proteins, and is involved in anti-inﬂamma-
tory, proapoptotic, autophagic, and cell surface attachment
functions (Menon et al., 1993; Momchilova and
Markovska, 1999; Ichimura et al., 2000; Okamoto et al.,
2004; Raetz et al., 2007; Braverman and Moser, 2012;
Rockenfeller et al., 2015). PE also plays an integral role in
membrane architecture via its unique biophysical properties
Figure 2 Outcomes of the p.Arg112Pro EPT1 sequence alteration. Yeast cells devoid of endogenous ethanolaminephosphotransferase
activity were transformed with plasmids bearing wild-type human EPT1 (hEPT1) or EPT1 containing the p.Arg112Pro mutation (hEPT1*) each
tagged with a DDK epitope. (A) Schematic representation of the CDP-ethanolamine branch of Kennedy pathway showing the role of EPT1 in PE
formation. CK = choline kinase; CPT = choline phosphotransferase; CT = phosphocholine cytidylyltransferase; EK = ethanolamine kinase;
ET = phosphoethanolamine cytidylyltransferase; Etn = ethanolamine; LPEAT = lyso-PE acyltransferase; PSD = phosphatidyl serine decarboxylase;
PSS = phophatidyl serine synthase. (B) Western blot versus whole cell extracts (WCE), which were fractionated into soluble (S100) and
membrane (P100) fractions, and probed using anti-DDK antibodies. Pgk1 and Dpm1 are soluble and membrane fraction loading and fractionation
purification controls, respectively. EV = empty vector control. (C) Mid-log phase cells were radiolabelled with 14C-ethanolamine for 1 h. As a
positive control yeast strain HJ001 (cpt1::LEU2) transformed with an empty vector was also radiolabelled; this strain possess the wild-type
genomic allele of yeast EPT1 (yEPT1). Cells were processed for lipid extraction and the radioactivity associated with PE and PC was determined.
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that are essential for key cell division and membrane fusion
processes (Mileykovskaya and Dowhan, 2005; Signorell
et al., 2009). These properties are conferred by the shape
of PE and its ability to form reverse non-lamellar structures.
The Kennedy pathway is the main biosynthetic route for
PE in most mammalian cells including the brain (Zelinski
and Choy, 1982; Tijburg et al., 1989; Arthur and Page,
1991). The ﬁnal step of this Kennedy pathway transfers
phosphoethanolamine from CDP-ethanolamine to a lipid
anchor such as DAG, and is catalysed by two known en-
zymes; EPT1 and CEPT1 (Henneberry and McMaster,
1999; Henneberry et al., 2002; Wright and McMaster,
2002; Schuiki and Daum, 2009). Here we identify auto-
somal recessive p.Arg112Pro alteration of EPT1 in patients
with a complex form of HSP. Our enzyme activity studies
show a markedly deleterious effect of the substitution on
EPT1 catalytic activity. This may be predicted to lead to
altered PE fatty acyl Kennedy pathway content and/or syn-
thesis, and the potentially signiﬁcant alterations to some PE
species detected in blood of patients may be consistent with
this. Notably, we detected no clear alteration in overall PE
content in blood. This may be explained by compensatory
activity of CEPT that synthesises PE from the same biochem-
ical source (CDP-ethanolamine), or by the synthesis of PE
from PS, either of which may potentially mask changes in
speciﬁc species PE levels arising due to EPT1 mutation. Thus
despite the apparent normalization of total PE levels in
blood, potential differences with respect to PE level in the
CNS, which could not be assessed in this study, or the
abnormalities that we detected in levels of speciﬁc PE species
in blood, seem likely to account for the clinical features
associated with EPT1 mutation. Consistent with this, there
is some clinical overlap between the affected individuals
described here with those of PE plasmalogen deﬁciency dis-
orders such as rhizomelic chondrodysplasia punctata
(RCDP), a condition characterized by skeletal abnormalities.
While there are signiﬁcant clinical differences between these
disorders, cleft palate, spasticity and neuroimaging ﬁndings
consistent with hypomyelination are features of both condi-
tions, which may be indicative of a common outcome on
developmental pathways and neuromorphogenesis due to
aberrant PE biosynthesis and reduced levels of plasmalogens,
substantial components of myelin.
Taken together, our ﬁndings provide new and important
insight into the biological role of the Kennedy pathway in
mammalian development and neurological function, and
document the ﬁrst human disorder arising due to
Kennedy pathway dysfunction.
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